Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases
HPB, Volume 14, No. 7, Year 2012
Notification
URL copied to clipboard!
Description
Objectives: Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of metastatic CRC, although data regarding its effect on post-embolization liver regeneration and tumour growth are conflicting. The objective of this observational study was to assess the impact of pre-embolization bevacizumab on liver hypertrophy and tumour growth. Methods: Computed tomography scans before and 4 weeks after PVE were evaluated in patients who received perioperative chemotherapy with or without bevacizumab. Scans were compared with scans obtained in a control group in which no PVE was administered. Future liver remnant (FLR), total liver volume (TLV) and total tumour volume (TTV) were measured. Bevacizumab was discontinued ≥ 4 weeks before PVE. Results: A total of 109 patients and 11 control patients were included. Portal vein embolization induced a significant increase in TTV: the right lobe increased by 33.4% in PVE subjects but decreased by 34.8% in control subjects (P < 0.001), and the left lobe increased by 49.9% in PVE subjects and decreased by 33.2% in controls (P= 0.022). A total of 52.8% of the study group received bevacizumab and 47.2% did not. There was no statistical difference between the two chemotherapy groups in terms of tumour growth. Median FLR after PVE was similar in both groups (28.8% vs. 28.7%; P= 0.825). Conclusions: Adequate liver regeneration was achieved in patients who underwent PVE. However, significant tumour progression was also observed post-embolization. © 2012 International Hepato-Pancreato-Biliary Association.
Authors & Co-Authors
Simoneau, E.
Saudi Arabia
Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery
Aljiffry, Murad M.
Saudi Arabia
Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery
Saudi Arabia, Jeddah
King Abdulaziz University
Salman, Ayat
Saudi Arabia
Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery
Abualhassan, Nasser
Saudi Arabia
Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery
Cabrera, Tatiana
Canada, Montreal
Centre Universitaire de Santé Mcgill
Valenti, David
Canada, Montreal
Centre Universitaire de Santé Mcgill
El Baage, Arwa
Saudi Arabia, Riyadh
College of Medicine
Jamal, Mohammad H.
Saudi Arabia
Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery
Kavan, Petr
Canada, Montreal
Centre Universitaire de Santé Mcgill
Al-Abbad, Saleh
Saudi Arabia
Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery
Chaudhury, Prosanto
Saudi Arabia
Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery
Hassanain, Mazen M.
Saudi Arabia
Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery
Canada, Montreal
Centre Universitaire de Santé Mcgill
Saudi Arabia, Riyadh
College of Medicine
Metrakos, Peter P.
Saudi Arabia
Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery
Saudi Arabia, Riyadh
College of Medicine
Statistics
Citations: 76
Authors: 13
Affiliations: 4
Identifiers
Doi:
10.1111/j.1477-2574.2012.00476.x
ISSN:
1365182X
e-ISSN:
14772574
Research Areas
Cancer
Study Design
Randomised Control Trial